Блог
Обновления исследований, изменения в законодательстве и анализ из мира психоделической науки.
Этот раздел пока доступен на английском языке.
A trial map pin is a starting point: read the dates and eligibility in the source record
2026-09-25
A nearby marker and a future completion date can look promising. Here is a short way to check what the original ClinicalTrials.gov record actually says.
What will the study measure? Read the outcomes before you read a headline
2026-09-26
An outcome measure describes what researchers plan to count or assess. Its title, description and time frame make a study claim much easier to check later.
ClinicalTrials.gov study status: what it tells you and what it doesn’t
2026-09-27
Recruiting, active but not recruiting, and completed describe different points in a study’s timeline. Learn how to compare study and location status without reading more into those labels than they say.
What Executive Order 14401 says about psychedelic research and ibogaine
2026-09-28
Executive Order 14401 directs federal support for state psychedelic programs and sets conditional agency tasks. Its $50 million allocation is not ibogaine-only funding, and the order does not approve a treatment.
What FDA's July 2026 psychedelic-trial guidance means
2026-10-21
FDA's July 2026 guidance explains considerations for psychedelic drug research. Here is its scope, and why final guidance is not a treatment approval.
FDA's September psychedelic hearing: what it covered
2026-10-17
The September hearing comment window has closed. Here is what the notice asked, and how the separate ibogaine research consultation differs.
Recruiting Phase 2 Trial Compares Group and Individual MDMA-Assisted Therapy for PTSD After October 7
2026-03-31
NCT07469098 is a recruiting, randomized, parallel, open-label phase 2 non-inferiority trial sponsored by Sheba Medical Center. It estimates 168 participants and completion in March 2029. No results are posted, and allocation is randomized rather than participant-selected.
What a small study found after first psilocybin use
2026-10-22
A study of 28 healthy volunteers found changes in brain signals and MRI measurements. It offers clues about psilocybin's effects, rather than proof of lasting therapeutic rewiring.
How to Participate in Psychedelic Clinical Trials
2026-06-08
ClinicalTrials.gov can help you find a study, but neither the registry nor PsychoactiveMap enrolls participants. Check official status, eligibility and contact details, then discuss risks, consent, time and costs with the study team and your clinician.
How to read ClinicalTrials.gov phase labels: what Phase 1, 2 and 3 do and do not mean
2026-09-29
Phase labels describe parts of a drug-development research program. They do not establish that an intervention is approved, safe, effective for an individual, or available outside the study.
A guide to Psychoactive Map’s legislation layer
2026-09-06
The legislation layer helps you find source-linked records by place and compound. This guide explains its limited coverage, map colors, source details, and correction process.
DT120's Panorama trial: how to read the anxiety results
2026-10-19
Panorama reported a 5.1-point advantage over placebo. Read the comparison, safety reporting, blinding limitations and current registry status.
Psilocybin and post-treatment Lyme disease: an early pilot study
2026-10-20
Twenty participants reported symptom improvements after supported psilocybin sessions. Without a control group, the study cannot show how much improvement was caused by the intervention.
Why placebo controls are tricky in psychedelic trials
2026-10-16
A trial can hide treatment assignments while the experience still gives people clues. Here is how researchers address that problem and how to read the design.
How to tell a trial listing from study results
2026-09-23
A registered study describes a research plan. Learn where to look for results and how to keep the two separate.
Proposed S. 4031 Would Create VA Innovative-Therapies Centers and Authorize $30M Annually
2026-03-26
Introduced S. 4031 would direct the VA to designate at least five innovative-therapies centers and authorize $30 million per fiscal year for research and education, subject to appropriations. The bill is not enacted and guarantees neither construction nor funding.
2C-B, MDMA and psilocybin: what a 24-person comparison found
2026-10-18
A controlled study compared acute effects in healthy volunteers. Its findings help characterize 2C-B, but do not establish that it is a safer treatment.
Sponsor, study site and contact: which one do you need?
2026-09-24
An organisation name, a map marker and a study contact serve different purposes. Here is how to find the right details in the original record.